Successful Fidaxomicin Hospital Discharges of Adult Patients With Clostridioides difficile Infections Post-2021 Guidelines: Are Economic Barriers Finally Coming Down?

We reviewed Clostridioides difficile-positive patients discharged on fidaxomicin after local adoption of 2021 C. difficile infection (CDI) guidelines. From 14 June to 3 October 2021, 80% (12/15) had copayments of $0-$35 and 27% (4/15) required prior authorization. The 30-day CDI recurrence was 7%.

Automated summary

This study reviewed the discharge of Clostridioides difficile-positive patients treated with fidaxomicin after local adoption of the 2021 CDI guidelines. From June 14 to October 3, 2021, 80% (12/15) of the patients had copayments ranging from $0 to $35, and 27% (4/15) required prior authorization. The 30-day CDI recurrence rate was 7%.